Approach to the new oral anticoagulants in family practice: Part 1: Comparing the options;Approche à l'égard des nouveaux anticoagulants oraux en pratique familiale: Lre partie : Comparer les options

Canadian Family Physician

Volumn 60, Issue 11, 2014, Pages

  Douketis, James ^a   Bell, Alan David ^b   Eikelboom, John ^a   Liew, Aaron ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; CLARITHROMYCIN; DABIGATRAN; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; QUINIDINE; RIFAMPICIN; RITONAVIR; RIVAROXABAN; VERAPAMIL; WARFARIN; ANTICOAGULANT AGENT; ANTIDOTE; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ANTICOAGULANT THERAPY; BLOOD ANALYSIS; BLOOD CLOTTING TEST; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG CONTRAINDICATION; DYSPEPSIA; EVIDENCE BASED PRACTICE; FOLLOW UP; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GENERAL PRACTICE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE RENAL IMPAIRMENT; VENOUS THROMBOEMBOLISM; ACUTE DISEASE; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; DRUG MONITORING; ORAL DRUG ADMINISTRATION; STROKE;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIDOTES; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DABIGATRAN; DRUG MONITORING; FAMILY PRACTICE; HUMANS; MORPHOLINES; PYRAZOLES; PYRIDONES; RIVAROXABAN; STROKE; THIOPHENES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84911447847     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Pradaxa [product monograph]. Burlington, ON: Boehringer Ingelheim Canada;2012.
2. Xarelto [product monograph]. Toronto, ON: Bayer Inc;2013.
3. Eliquis [product monograph]. Montreal, QC: Bristol-Myers Squibb;2012.
4. Skanes AC, Healey JS, Cairns JA, Dorian P, Gillis AM, McMurtry MS, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28(2):125-36.
5. Douketis J, Bell AD, Eikelboom J, Liew A. Approach to the new oral anticoagulants in family practice. Part 2: addressing frequently asked questions. Can Fam Physician 2014;60:997-1001 (Eng), e504-11 (Fr).
6. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369(13):1206-14.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh J, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51.
8. Erratum in: N Engl J Med 2010;363(19):1877.
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91.
10. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365(11):981-92.
11. Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-Analysis of the literature. Circulation 2012;126(20):2381-91.
12. Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-Analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol 2013;36(2):61-7.
13. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376(9745):975-83.
14. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52.
15. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363(26):2499-510.
16. Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013;368(8):709-18.
17. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013;368(8):699-708.
18. Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012;157(11):796-807.
19. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med 2013;368(14):1272-4.
20. Patel MR, Hellkamp AS, Lokhnygina Y, Puccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013;61(6):651-8.
21. Dossett LA, Riesel JN, Griffin MR, Cotton BA. Prevalence and implications of preinjury warfarin use: an analysis of the National Trauma Databank. Arch Surg 2011;146(5):565-70.
22. Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost 2011;105(5):908-19.
23. McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, et al. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: a Canadian analysis using the Ontario Ministry of Health Perspective. J Med Econ 2012;15(5):817-28.
24. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364(9):806-17.
25. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60(8):738-46.
26. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-Analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5(5):711-9.
27. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012;108(3):476-84.
28. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e531S-75S.
29. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 2012 Focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719-47.
30. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2011;155(10):660-7, W204.
31. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012;380(9855):1749-58.
32. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11(4):315-22.
33. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding-A systematic review and metaanalysis. Gastroenterology 2013;145(1):105-12.
34. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013;369(9):799-808.
35. Lehr T, Haertter S, Liesenfeld KH, Staab A, Clemens A, Reilly PA, et al. Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 2012;52(9):1373-8.
36. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32(19):2387-94.
37. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna H, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33(22):2821-30.
38. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e44S-88S.
39. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract 2010;64(7):956-67.
40. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013;127(5):634-40.
41. Fitchett DH, Theroux P, Brophy JM, Cantor WJ, Cox JL, Gupta M, et al. Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment-part 2: ST-segment elevation myocardial infarction. Can J Cardiol 2011;27(Suppl A):S402-12.
42. Komó csi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-Analysis of randomized controlled trials. Arch Intern Med 2012;172(20):1537-45.
43. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, et al. New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-Analysis. Eur Heart J 2013;34(22):1670-80.
44. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;366(1):9-19.
45. Gibson CM, Chakrabarti AK, Mega J, Bode C, Bassand JP, Verheuqt FW, et al. Reduction of stent thrombosis in patients with acute coronary syndrome treated with rivaroxaban in ATLAS ACS 2-TIMI 51. J Am Coll Cardiol 2013;62(4):286-90.
46. Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol 2013;61(18):1853-9.
47. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med 2010;363(19):1875-6.
48. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation 2012;125(5):669-76.
49. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-Analysis of noninferiority randomized controlled trials. Arch Intern Med 2012;172(5):397-402.
50. Lip GY, Lane DA. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients? Am J Med 2010;123(9):785-9.
51. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, et al. Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 2013;35(2):295-301.
52. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des 2010;16(31):3436-41.
53. Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 2013;52(4):243-54.
54. Thrombosis Canada [website]. Clinical guides. Hamilton, ON: Thrombosis Canada. Available from: http://thrombosiscanada.ca/?page-id=18. Accessed 2014 Sep 23.